Clinical Trial Update: A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating GSK573719/Vilanterol (125/25 mcg) and components in COPD completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• GSK573719/Vilanterol (125/25 mcg)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 3 | Status: COMPLETED | Results posted: 2014-02-10